FDA Skeptical of Experimental ALS Treatment Pushed by Patient Advocates

In documents posted Monday, the FDA reiterated its longstanding position that drugmaker Brainstorm's lone study doesn't provide convincing evidence that its stem cell-based therapy helps patients with ALS, or amyotrophic lateral sclerosis.
Source: Arkansas Business - Health Care - Category: American Health Source Type: news